Search
Search Results
-
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
BackgroundAlzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally....
-
Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists
BackgroundAlzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize...
-
VascuConNet: an enhanced connectivity network for vascular segmentation
Medical image segmentation commonly involves diverse tissue types and structures, including tasks such as blood vessel segmentation and nerve fiber...
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early...
-
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
The amyloid cascade hypothesis is a useful framework for therapeutic development in Alzheimer’s disease (AD). Amyloid b 1-42 (Aβ) has been the main...
-
DCNN-based prediction model for detection of age-related macular degeneration from color fundus images
AbstractAge-related macular degeneration (AMD) is a degenerative disorder in the macular region of the eye. AMD is the leading cause of irreversible...
-
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s disease mice
BackgroundAmyloid-related imaging abnormalities (ARIA) have been identified as the most common and serious adverse events resulting from pathological...
-
Passive immunotherapy for Alzheimer’s disease: challenges & future directions
Passive immunotherapy with specific antibodies targeting Amyloid β (Aβ) peptide or tubulin-associated unit (tau) protein has emerged as a promising...
-
-
The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond
CLARITY-AD is an 18-month, double-blinded, placebo-controlled, phase 3 trial which examined the safety and efficacy of the anti-amyloid agent,...
-
Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer’s disease treatment
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and neuronal abnormalities. Current therapies...
-
Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which...
-
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
BackgroundThis review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development...
-
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)
BackgroundAnti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer’s disease (AD). However, Aβ peptide adopts...
-
The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer
BackgroundThe androgen receptor (AR) is a drug target used to inhibit AR and prostate cancer (PCa) growth. Surprisingly, treatment with...
-
Emerging diagnostics and therapeutics for Alzheimer disease
Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have...
-
Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia
This narrative review focuses on the role of cholesteryl ester transfer protein (CETP) and peripheral lipoproteins in the vascular contributions to...
